These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 10454207)

  • 1. Inhibitors of protein kinases: CGP 41251, a protein kinase inhibitor with potential as an anticancer agent.
    Fabbro D; Buchdunger E; Wood J; Mestan J; Hofmann F; Ferrari S; Mett H; O'Reilly T; Meyer T
    Pharmacol Ther; 1999; 82(2-3):293-301. PubMed ID: 10454207
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential inhibition of the epidermal growth factor-, platelet-derived growth factor-, and protein kinase C-mediated signal transduction pathways by the staurosporine derivative CGP 41251.
    Andrejauskas-Buchdunger E; Regenass U
    Cancer Res; 1992 Oct; 52(19):5353-8. PubMed ID: 1394140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CGP 41251 and tamoxifen selectively inhibit mitogen-activated protein kinase activation and c-Fos phosphoprotein induction by substance P in human astrocytoma cells.
    Luo W; Sharif TR; Houghton PJ; Sharif M
    Cell Growth Differ; 1997 Nov; 8(11):1225-40. PubMed ID: 9372245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PKC412--a protein kinase inhibitor with a broad therapeutic potential.
    Fabbro D; Ruetz S; Bodis S; Pruschy M; Csermak K; Man A; Campochiaro P; Wood J; O'Reilly T; Meyer T
    Anticancer Drug Des; 2000 Feb; 15(1):17-28. PubMed ID: 10888033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class.
    Buchdunger E; Zimmermann J; Mett H; Meyer T; Müller M; Regenass U; Lydon NB
    Proc Natl Acad Sci U S A; 1995 Mar; 92(7):2558-62. PubMed ID: 7708684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A high throughput system for the evaluation of protein kinase C inhibitors based on Elk1 transcriptional activation in human astrocytoma cells.
    Sharif TR; Sharif M
    Int J Oncol; 1999 Feb; 14(2):327-35. PubMed ID: 9917510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative.
    Buchdunger E; Zimmermann J; Mett H; Meyer T; Müller M; Druker BJ; Lydon NB
    Cancer Res; 1996 Jan; 56(1):100-4. PubMed ID: 8548747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of cell growth: effects of the tyrosine kinase inhibitor CGP 53716.
    Major TC; Keiser JA
    J Pharmacol Exp Ther; 1997 Oct; 283(1):402-10. PubMed ID: 9336349
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A derivative of staurosporine (CGP 41 251) shows selectivity for protein kinase C inhibition and in vitro anti-proliferative as well as in vivo anti-tumor activity.
    Meyer T; Regenass U; Fabbro D; Alteri E; Rösel J; Müller M; Caravatti G; Matter A
    Int J Cancer; 1989 May; 43(5):851-6. PubMed ID: 2714889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of the growth of glioblastomas by CGP 41251, an inhibitor of protein kinase C, and by a phorbol ester tumor promoter.
    Begemann M; Kashimawo SA; Choi YA; Kim S; Christiansen KM; Duigou G; Mueller M; Schieren I; Ghosh S; Fabbro D; Lampen NM; Heitjan DF; Schiff PB; Bruce JN; Weinstein IB
    Clin Cancer Res; 1996 Jun; 2(6):1017-30. PubMed ID: 9816263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.
    Wood JM; Bold G; Buchdunger E; Cozens R; Ferrari S; Frei J; Hofmann F; Mestan J; Mett H; O'Reilly T; Persohn E; Rösel J; Schnell C; Stover D; Theuer A; Towbin H; Wenger F; Woods-Cook K; Menrad A; Siemeister G; Schirner M; Thierauch KH; Schneider MR; Drevs J; Martiny-Baron G; Totzke F
    Cancer Res; 2000 Apr; 60(8):2178-89. PubMed ID: 10786682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and synthesis of novel tyrosine kinase inhibitors using a pharmacophore model of the ATP-binding site of the EGF-R.
    Traxler P; Furet P; Mett H; Buchdunger E; Meyer T; Lydon N
    J Pharm Belg; 1997; 52(2):88-96. PubMed ID: 9193132
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The protein kinase C inhibitor CGP 41251, a staurosporine derivative with antitumor activity, reverses multidrug resistance.
    Utz I; Hofer S; Regenass U; Hilbe W; Thaler J; Grunicke H; Hofmann J
    Int J Cancer; 1994 Apr; 57(1):104-10. PubMed ID: 7908658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A protein kinase C inhibitor induces phenotypic reversion of ras-transformed pancreatic cancer cells and cooperatively blocks tumor cell proliferation with an anti- ras peptide.
    Way D; Smith S; Sivendran S; Chie L; Kanovsky M; Brandt-Rauf PW; Chung DL; Michl J; Pincus MR
    Cancer Chemother Pharmacol; 2002 Jun; 49(6):429-37. PubMed ID: 12107546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Staurosporine analogues - pharmacological toys or useful antitumour agents?
    Gescher A
    Crit Rev Oncol Hematol; 2000 May; 34(2):127-35. PubMed ID: 10799837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A dual inhibitor of platelet-derived growth factor beta-receptor and Src kinase activity potently interferes with motogenic and mitogenic responses to PDGF in vascular smooth muscle cells. A novel candidate for prevention of vascular remodeling.
    Waltenberger J; Uecker A; Kroll J; Frank H; Mayr U; Bjorge JD; Fujita D; Gazit A; Hombach V; Levitzki A; Böhmer FD
    Circ Res; 1999 Jul; 85(1):12-22. PubMed ID: 10400906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro pharmacological characterization of PD 166285, a new nanomolar potent and broadly active protein tyrosine kinase inhibitor.
    Panek RL; Lu GH; Klutchko SR; Batley BL; Dahring TK; Hamby JM; Hallak H; Doherty AM; Keiser JA
    J Pharmacol Exp Ther; 1997 Dec; 283(3):1433-44. PubMed ID: 9400019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors.
    Buchdunger E; Cioffi CL; Law N; Stover D; Ohno-Jones S; Druker BJ; Lydon NB
    J Pharmacol Exp Ther; 2000 Oct; 295(1):139-45. PubMed ID: 10991971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterisation of novel human lung carcinoma cell lines selected for resistance to anti-neoplastic analogues of staurosporine.
    Courage C; Bradder SM; Jones T; Schultze-Mosgau MH; Gescher A
    Int J Cancer; 1997 Nov; 73(5):763-8. PubMed ID: 9398059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Basic fibroblast growth factor induces expression of VEGF receptor KDR through a protein kinase C and p44/p42 mitogen-activated protein kinase-dependent pathway.
    Hata Y; Rook SL; Aiello LP
    Diabetes; 1999 May; 48(5):1145-55. PubMed ID: 10331422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.